Semax vs Omberacetam (Noopept)
Both have limited older human literature but different molecular classes, routes and populations; neither has modern large healthy-cognition evidence.
| Attribute | Semax | Omberacetam (Noopept) |
|---|---|---|
| Human evidence | Older regional stroke and rehabilitation studies report neurological/functional signals and BDNF changes, but this evidence does not establish healthy-person cognitive enhancement. | Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified. |
| Research focus | Stroke/neuroprotection and cognitive research | Post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic |
| Regulatory status | Not FDA/EMA-approved; US compounding status has been under FDA review. | FDA substance records identify omberacetam/Noopept but explicitly note that UNII listing does not imply regulatory review or approval. Regulatory status varies internationally. |
| Route / formulation | Do not convert regional clinical use into a general cognitive-enhancement claim. | Most clinical literature concerns oral use in neurologic patients; it should not be extrapolated to other formulations or healthy-user 'nootropic' protocols. |
Why these are compared
These compounds appear in the brain & cognitive performance evidence landscape, but they are not interchangeable. Semax is acth(4-7)-derived synthetic peptide analogue studied in stroke/neuroprotection and cognitive research; Omberacetam (Noopept) is synthetic peptidomimetic / dipeptide-derived small molecule studied in post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Semax: Limited/regional human stroke evidence; no established healthy nootropic efficacy.
Omberacetam (Noopept): Limited older human clinical evidence; healthy cognitive enhancement unestablished.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No robust direct head-to-head trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.